Exor has extended its agreement with Philips, allowing the Dutch health technology company's largest shareholder to increase its holding to as much as 22% of issued ordinary share capital and voting rights from 20%. Any move above that level would still need approval from Philips' supervisory board, while existing governance terms, including Exor's right to nominate one supervisory board member, remain unchanged. Philips said the revision reflects Exor's long-term backing for management's 2026-2028 plan and focus on profitable growth, and the shares rose about 0.85% to $27.17 in Tuesday premarket trading. Exor first disclosed a 15.1% stake in August 2023 while Philips was dealing with fallout from a 2021 product recall, and it later raised the holding to 19% in 2025.